Gene therapy using adenoviral ( Ad ) vector containing herpes simplex virus thymidine kinase ( AxCAHSV -tk ) followed by the administration of ganciclovir ( GCV ) has been a promising therapy for cancer including malignant gliomas. However, there remain numerous problems to overcome, such as the high immunogenicity and toxicity of Ad vector. To optimize the therapy, we investigated whether a conjugation of our original cationic liposomes and Ad vectors reduces viral antigenicity and maintains the antitumor activity in mouse experimental ( subcutaneous and intracranial ) glioma models. Our original liposomes consist of N -(a -trimethylammonioacetyl ) -didodecyl -D -glutamate chloride, dilauroyl phosphatidylcholine, and dioleoyl phosphatidylethanolamine in a molar ratio of 1:2:2. AxCAHSV -tk and GCV showed a remarkable inhibition of experimental glioma growth. The growth -inhibitory effect decreased in mice previously immunized with another Ad vector ( AxCALacZ ). In contrast, the conjugation of AxCAHSV -tk and liposomes did not diminish the growth -inhibitory effect. Furthermore, the conjugation reduced antigenicity for Ad vector in vivo. These findings suggest that suicide gene therapy, using a conjugation of AxCAHSV -tk and our liposomes, is a feasible approach for human cancer gene therapy, especially malignant gliomas.
T he conventional treatment for malignant glioma is largely ineffective. Gene therapy was initially thought of as a means to correct single gene defects in hereditary disease. Recently, cancer has become an important indication for gene therapy development. However, current gene therapy for cancer still presents some major problems including low transduction efficiency and toxicity of vectors. At present, viral and nonviral methods of gene transfer are used as vectors for clinical trials. The most important viral vectors are retroviruses, adenoviruses, adeno -associated viruses, and herpes viruses. Among them, adenoviral ( Ad ) vectors have the highest transduction efficiency in various cancer cells. Therefore, Ad vector is one of the promising vectors for the gene therapy of cancers including malignant glioma. However, Ad vectors have high immunogenicity, which limits the success of gene transfer or redosing.
Cationic liposomes are also very promising vectors, which efficiently entrap DNA as well as drugs and have been widely used in the field of basic molecular biology and for gene therapy. We developed our original cationic liposomes composed of N -(a-trimethylammonioacetyl ) -didodecyl -D -glutamate chloride ( TMAG ), dilauroyl phosphatidylcholine (DLPC ), and dioleoyl phosphatidyl -ethanolamine ( DOPE ) in a molar ratio of 1:2:2. We subsequently prepared two kinds of the liposomes, multilamellar vesicles (MLVs ) and small unilamellar vesicles (SUVs ), for cancer gene therapy. We started a clinical trial for patients with malignant gliomas using the MLV liposomes containing human binterferon gene. We recently found that our original SUV liposome -conjugated Ad vector (Ad /SUV ) resulted in a 10 -fold higher transduction efficiency in human glioma cell lines in vitro than Ad vector alone and that no additional toxicity was induced by SUV conjugation. 1 Furthermore, we also found that Ad /SUV reduced antigenicity for Ad vector in vivo. 2 In this paper, we investigated whether Ad / SUV, compared to Ad vector alone, can induce a more effective antitumor activity against experimental (subcutaneous [s.c. ] and intracranial ) glioma models in mice.
Materials and methods

Cell line
The mouse glioma cell line, GL261, was used in the experiments. This line was originally induced in the brain of a B6 mouse by intracerebral implantation of methylcholanthrene. 3 The cells were cultured in Eagle's minimum essential medium ( MEM ) supplemented with 10% fetal calf serum, 2 mM nonessential amino acids, 5 mM L -glutamine, streptomycin (100 g /mL ), and penicillin (100 U /mL ).
Vectors
The Ad vector containing the herpes simplex virus thymidine kinase (HSV-tk ) gene under transcriptional control of the chicken b -actin promoter and cytomegalovirus enhancer ( CAG promoter ) (AxCAHSV-tk ) was constructed using an Adenovirus Expression Vector Kit ( Takara, Otsu, Japan ). Another Ad vector expressing b -galactosidase (AxCALacZ ) was a gift from Dr Izumu Saito (University of Tokyo, Tokyo, Japan ).
Mouse
The animals used were 8 -to 12 -week -old female B6 mice ( SLC, Shizuoka, Japan ). They were kept under pathogenfree conditions in the animal facility of Nagoya University. Animal experiments were performed according to the principles enunciated in the Guide for the Care and Use of Laboratory Animals prepared by the Office of the Prime Minister of Japan.
Gene transfer and ganciclovir ( GCV ) administration
S.c. model. Fragments of tumors ( 3 mm in diameter ) were transplanted s.c. into the backs of mice by means of a trocar needle. When the transplanted tumors had grown to 10 mm in diameter, we injected the AxCALacZ (10 7 pfu/15 L) or AxCALacZ /SUV ( 10 7 pfu /15 L ) into the tumor. Ten days later, we evaluated the transduction efficiency by bgalactosidase assay.
Also, when transplanted tumors had grown to 6-7 mm in diameter, the mice were divided randomly into the following six treatment groups: group 1, one intratumoral injection of phosphate -buffered saline ( PBS ) (15 L ); group 2, one intratumoral injection of AxCALacZ ( 10 7 pfu /15 L); group 3, one intratumoral injection of AxCAHSV-tk and GCV (10 7 pfu /15 L and 10 mg /kg ); group 4, one intratumoral injection of AxCAHSV-tk /SUV and GCV ( 10 7 pfu /15 L and 10 mg /kg ); group 5, three intratumoral injections of AxCAHSV-tk and GCV (10 7 pfu /15 L and 10 mg /kg ); group 6, three intratumoral injections of AxCAHSV-tk /SUV and GCV ( 10 7 pfu /15 L and 10 mg /kg ). Ad vector ( 10 7 pfu / 15 L ) was injected into s.c. tumors on day 0 (single injection ) or on days 0, 4, and 8 ( three injections). In the case of a single injection, 10 mg / kg GCV was administered intraperitoneally ( i.p. ), twice daily, in 0.5 mL of saline for 6 days after vector injection.
Following three injections, the same volume of GCV was administered i.p., twice daily, in 0.5 mL of saline for 2 days after vector injection and the procedure was repeated three times.
Intracranial model. Mice were anesthesized with an i.p. injection of pentobarbital (60 -70 mg / kg body weight ), and after hair shaving and scalp incision, a burr hole was made in the skull 3 mm lateral to the midline and 4 mm posterior to the bregma using a dental drill. The head of each mouse was fixed in a stereotactic apparatus with ear bars. Then 2Â10 5 GL261 cells in 2 L of PBS were injected stereotactically over 4 minutes at a depth of 2 mm below the dura mater. A sterile Hamilton syringe fitted with a 26-gauge needle was used with a microsyringe pump. The needle was left in the brain for an additional 2 minutes and then was slowly withdrawn. The mice were divided randomly into the following five treatment groups: group A, one intracranial injection of PBS ( 2 L ); group B, one intracranial injection of AxCAHSV-tk and GCV ( 10 7 pfu / 2 L and 10 mg /kg); group C, one intracranial injection of AxCAHSV-tk / SUV and GCV (10 7 pfu /2 L and 10 mg /kg); group D, three intracranial injections of AxCAHSV-tk and GCV (10 7 pfu / 2 L and 10 mg / kg); and group E, three intracranial injections of AxCAHSV-tk /SUV and GCV ( 10 7 pfu/2 L and 10 mg /kg ). Ad vector (10 7 pfu /2 L ) was injected into intracranial tumors on day 4 ( single injection) or on days 4, 8, and 12 (three injections) after tumor injection. In the case of a single injection, 10 mg /kg GCV was administered i.p., twice daily, in 0.5 mL of saline for 6 days after vector injection. Following three injections, the same volume of GCV was administered i.p., twice daily, in 0.5 mL of saline for 2 days after vector injection and the procedure was repeated three times.
Evaluation of growth inhibition
S.c. model. The inhibition of s.c. tumor growth was evaluated by measuring the tumor size every fifth day with the aid of microcalipers. Tumor volume was calculated by the formula ab 2 / 2, where a is the width and b is the length of the tumor. The relative tumor volume was calculated according to T n /T 0 Â100( % ), where T 0 = tumor volume immediately before intratumoral injections and T n = tumor volume after injections.
Intracranial model. The growth -inhibitory effects were evaluated by direct measurement of tumor size, length (L ), and width ( W ) from H&E staining of coronal sections. The tumor volume (V ) was calculated according to the following formula:
Statistical analysis was performed using Student's t-test.
Quantitative analysis of anti -Ad antibody
To test whether Ad /SUV was less antigenic in vivo, AxCALacZ / SUV and an equivalent dose of AxCALacZ (10 7 pfu ) were injected s.c. into B6 mice 2 weeks before
Cancer Gene Therapy The growth -inhibitory effect introduced by the AxCAHSV-tk and cationic liposome complex ( AxCAHSVtk /SUV ) followed by GCV treatment was assessed in mouse s.c. glioma. When transplanted tumors had grown to 6 -7 mm in diameter, we started the treatments. Tumors injected with PBS (control ) or AxCALacZ grew exponentially to a volume about 40 times their original size by day 45 after the first injection (Fig 1) . A single injection of AxCAHSV-tk followed by GCV suppressed the tumor growth slightly, and three injections did so more strongly. However, these suppressions were cytostatic. In contrast, a single injection of AxCAHSV-tk /SUV followed by GCV also suppressed the tumor growth, and three injections did far more strongly than AxCAHSV-tk alone. Furthermore, tumors disappeared completely within 50 days posttreatment in mice receiving three intratumoral injections of AxCAHSV-tk followed by GCV.
Inhibition of s.c. GL261 tumor growth after immunization by AxCaLacZ. To evaluate the influence of immunization by AxCALacZ in vivo, AxCALacZ / SUV and an equivalent dose of AxCALacZ (10 7 pfu ) were injected s.c. into B6 mice. Fourteen days later, we started the treatments described above. When the immunization was performed 14 days before treatments, the antitumor effect of the following pfu / 15 L and 10 mg / kg ); AxCAHSV -tk / SUV( 1 ), one intratumoral injection of AxCAHSV -tk / SUV and GCV ( 10 7 pfu / 15 L and 10 mg / kg ); AxCAHSV -tk( 3 ), three intratumoral injections of AxCAHSV -tk and GCV ( 10 7 pfu / 15 L and 10 mg / kg ); AxCAHSV -tk / SUV, three intratumoral injections of AxCAHSV -tk / SUV and GCV ( 10 7 pfu / 15 L and 10 mg / kg ). Ad vector ( 10 7 pfu / 15 L ) was injected into s.c. tumors on day 0 ( single injection ) or on days 0, 4, and 8 ( three injections ). In the case of a single injection, 10 mg / kg GCV was administered i.p., twice daily, in 0.5 mL of saline for 6 days after vector injection. Following three injections, the same volume of GCV was administered i.p., twice daily, in 0.5 mL of saline for 2 days after vector injection, and the procedure was repeated three times. N = 7. **P < .01; NS, not significant. Figure 2 Inhibition of s.c. glioma growth by AxCAHSV -tk followed by GCV, with preimmunization. AxCAHSV -tk( 3 ), three intratumoral injections of AxCAHSV -tk and GCV ( 10 7 pfu / 15 L and 10 mg / kg ) with no preimmunization; AxCAHSV -tk( 3 ) + , three intratumoral injections of AxCAHSV -tk and GCV ( 10 7 pfu / 15 L and 10 mg / kg ) with preimmunization. Ad vector ( 10 7 pfu / 15 L ) was injected into s.c. tumors on days 0, 4, and 8 ( three injections ). Following three injections, the same volume of GCV was administered i.p., twice daily, in 0.5 mL of saline for 2 days after vector injection, and the procedure was repeated three times. N = 7. *P < .05; **P < .01. Figure 3 Inhibition of s.c. glioma growth by AxCAHSV -tk / SUV followed by GCV, with preimmunization. AxCAHSV -tk / SUV( 3 ), three intratumoral injections of AxCAHSV -tk / SUV and GCV ( 10 7 pfu / 15 L and 10 mg / kg ) with no preimmunization; AxCAHSV -tk / SUV( 3 ) + , three intratumoral injections of AxCAHSV -tk / SUV and GCV ( 10 7 pfu / 15 L and 10 mg / kg ) with preimmunization. Ad vector ( 10 7 pfu / 15 L ) was injected into s.c. tumors on days 0, 4, and 8 ( three injections ). Following three injections, the same volume of GCV was administered i.p., twice daily, in 0.5 mL of saline for 2 days after vector injection, and the procedure was repeated three times. N = 7. All values present the mean and SD of five animals.
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AxCAHSV-tk and GCV treatment was suppressed significantly (Fig 2 ) . In contrast, the antitumor effect of the following AxCAHSV-tk /SUV and GCV treatment was not suppressed at all despite preimmunization ( Fig 3 ) .
Intracranial model
Growth inhibition of intracranial GL261 tumor. Mice that had been inoculated intracranially with GL261 cells were killed 28 days after tumor inoculation and then the growthinhibitory effect introduced by the AxCAHSV-tk and cationic liposome complex (AxCAHSV-tk /SUV ) followed by GCV treatment was assessed. The results were shown in Figure 4 . In groups D and E, tumor size was markedly decreased compared with other groups. Tumors of group E treated with AxCAHSV-tk /SUV three times showed a remarkable 3-fold reduction in volume compared with group D with AxCAHSV-tk (P < 0.01). Inhibition of intracranial GL261 tumor growth after immunization by AxCaLacZ. To evaluate the influence of immunization by AxCALacZ in vivo, AxCALacZ /SUV and an equivalent dose of AxCALacZ (10 7 pfu ) were injected s.c. into B6 mice. Fourteen days later, we started the treatments described above. When the immunization was performed 14 days before treatments, we obtained the same results as s.c. model. Namely, the antitumor effect of the following AxCAHSV-tk and GCV treatment was suppressed significantly ( Fig 5) . In contrast, the antitumor effect of the following AxCAHSV-tk / SUV and GCV treatment was not suppressed at all despite preimmunization ( Fig 5) .
Quantitative analysis of anti -Ad antibody in serum of treated mice
Fifteen days after the first injection of AxCAHSV-tk or AxCAHSV-tk /SUV, we measured the levels of anti -Ad antibody in serum of treated mice. The anti -Ad IgG level of mice receiving three intratumoral injections of AxCAHSVtk was 4326 ± 174 ng/mL. In contrast, the anti-Ad IgG level of mice receiving three intratumoral injections of AxCAHSV-tk /SUV was 848 ±56 ng /mL. Anti -Ad IgG levels from the former were 5.1 -fold lower than those from the latter ( Table 2 ) . Figure 4 Inhibition of intracranial glioma growth by AxCAHSV -tk or AxCAHSV -tk / SUV followed by GCV. Ad, intracranial injections of AxCAHSV -tk and GCV ( 10 7 pfu / 2 L and 10 mg / kg ); Ad / SUV, intratumoral injections of AxCAHSV -tk / SUV and GCV ( 10 7 pfu / 2 L and 10 mg / kg ). Ad vector ( 10 7 pfu / 2 L ) was injected into intracranial tumors on days 4, 8, and 12 ( three injections ). GCV was administered i.p., twice daily, in 0.5 mL of saline for 2 days after vector injection, and the procedure was repeated three times in the case of three injections. N = 5. Transverse bar, mean; **P < .01; ***P < .001; NS, not significant. Inhibition of intracranial glioma growth by AxCAHSV -tk or AxCAHSV -tk / SUV followed by GCV, with preimmunization. Ad, intracranial injections of AxCAHSV -tk and GCV ( 10 7 pfu / 2 L and 10 mg / kg ); Ad / SUV, intracranial injections of AxCAHSV -tk / SUV and GCV ( 10 7 pfu / 2 L and 10 mg / kg ). Im ( À ), with no preimmunization; Im ( + ), with preimmunization. Ad vector ( 10 7 pfu / 2 L ) was injected into intracranial tumors on days 4, 8, and 12 ( three injections ). GCV was administered i.p., twice daily, in 0.5 mL of saline for 2 days after vector injection, and the procedure was repeated three times in the case of three injections. N = 5. Transverse bar, mean; *P < .05; **P < .01; NS, not significant. All values present the mean and SD of six animals.
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In brief, 15 patients with recurrent malignant brain tumors were treated by this approach and antitumor activity was detected in five of the smaller tumors. However, the response of only very small tumors, in which a high density of vectorproducing cells had been placed, suggests that techniques to improve the delivery and distribution of the therapeutic gene will need to be developed if clinical utility is to be achieved with this approach. 5 Adenovirus vectors have a broad range of infection in humans and the capacity to transfer genes to nondividing cells such as neurons and glial cells in the brain. Furthermore, it is easier to prepare in large quantities, than other viral vectors. However, adenovirus vectors have some problems such as high immunogenicity and toxicity. Therefore, many investigators have been making efforts to resolve these problems. Strategies considered included the development of fiber or pentone -mutated recombinant adenovirus vectors or a conjugation of adenovirus vectors and liposomes. Beer et al 6 reported that the poly( lactic -glycolic ) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Kreuzer et al 7 indicated that adenovirus -assisted lipofection is efficient in in vitro gene transfer to human smooth muscle cells, and Raja -Walia et al 8 found that liposome-mediated gene transfer was enhanced in vascular tissue by replication -deficient adenovirus. Rainov et al investigated the intraarterial delivery of genetically engineered replication-deficient adenovirus vectors and cationic liposome -plasmid DNA complexes to experimental brain tumors. They concluded that an intracarotid application of adenovirus vectors and cationic liposome -plasmid DNA complexes can effectively transduce tumor cells in the brain. 9 Here we can confirm that conjugation of our original cationic liposomes and recombinant adenovirus vectors reduced immunogenicity and maintained anticancer activity. We have already used our original liposomes in patients with malignant glioma, and their safety is confirmed, facilitating clinical application.
Lambright et al 10 reported that multiple treatments using an Ad vector to deliver HSV-tk significantly improves survival in a murine i.p. tumor model, and that the presence of preexisting neutralizing antibodies does not blunt this effect. However, our present study indicated that the antitumor activity of Ad vectors alone was significantly decreased by preimmunization. In contrast, the antitumor activity of Ad / SUV did not decrease at all.
These findings suggest that cationic liposome conjugation with recombinant Ad vectors containing HSV-tk gene followed by GCV treatment can reduce viral antigenicity and maintain antitumor activity in an in vivo glioma model, and that it is a feasible approach for human cancer gene therapy, especially against malignant brain tumors.
